Compare · MRNA vs TCRX
MRNA vs TCRX
Side-by-side comparison of Moderna Inc. (MRNA) and TScan Therapeutics Inc. (TCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TCRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $56.03B, about 1209.1x TCRX ($46.3M).
- Over the past year, MRNA is up 521.4% and TCRX is down 61.9% - MRNA leads by 583.4 points.
- MRNA has been more active in the news (14 items in the past 4 weeks vs 5 for TCRX).
- MRNA has more recent analyst coverage (25 ratings vs 9 for TCRX).
- Company
- Moderna Inc.
- TScan Therapeutics Inc.
- Price
- -
- -
- Market cap
- $56.03B
- $46.3M
- 1M return
- +172.65%
- -7.66%
- 1Y return
- +521.42%
- -61.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 14
- 5
- Recent ratings
- 25
- 9
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
TScan Therapeutics Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Latest MRNA
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation
- Moderna upgraded by Argus with a new price target
- Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- Moderna upgraded by Wolfe Research
Latest TCRX
- SEC Form 8-K filed by TScan Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.
- SEC Form 10-Q filed by TScan Therapeutics Inc.
- TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- TScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
- Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
- SEC Form 4 filed by Director Baker Bros. Advisors Lp